Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Endocrine 1Dermatologic 1

Conditions

Melanoma 3Somatostatinoma 1Pheochromocytoma 1Insulinoma 1Glucagonoma 1Gastrinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Merkel Cell 1Carcinoma, Medullary 1Carcinoma, Islet Cell 1

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2veliparib 1vatalanib 1tipifarnib 1temsirolimus 1pentetreotide 1fludarabine phosphate 1Vinorelbine 1Temozolomide 1Sirolimus 1Ritonavir 1Radiotherapy 1Quality of Life 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Melphalan 1Ipilimumab 1Interleukin-13 1Indinavir 1Immunotherapy 1High-Energy Shock Waves 1Fluorodeoxyglucose F18 1Everolimus 1Drug Therapy 1Cyclophosphamide 1Capecitabine 1CTLA-4 Antigen 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pheochromocytoma × vatalanib × Dermatologic × Clear all
NCT00655655 2024-08-21

Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors

Mayo Clinic

Phase 1 Completed
96 enrolled
DermatologicEndocrineGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glucagonoma, Insulinoma, Melanoma, Pheochromocytoma, Somatostatinoma, Carcinoma, Merkel Cell, Gastrinoma, Carcinoma, Islet Cell, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡